0.68p+0.03 (+3.85%)23 Dec 2024, 16:14
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Provexis PLC Fundamentals

Company NameProvexis PLCLast Updated2024-12-23
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue2.263 bnMarket Cap£15.27 m
PE Ratio0.39Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio2.6132Cash Equity Ratio0.9935
Quick Ratio1.0240Current Ratio1.62
Price To Book Value21.0970ROCE0

Provexis PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Provexis PLC Company Financials

Assets2024202320222021
Tangible Assets0000
Intangible Assets0000
Investments0000
Total Fixed Assets0000
Stocks£136,520.00£327,797.00£85,808.00£60,576.00
Debtors£125,479.00£61,114.00£104,443.00£140,923.00
Cash & Equivalents£189,357.00£379,121.00£863,873.00£1.08 m
Other Assets0000
Total Assets£498,036.00£845,992.00£1.13 m£1.29 m
Liabilities2024202320222021
Creditors within 1 year£307,448.00£188,337.00£157,909.00£150,681.00
Creditors after 1 year0000
Other Liabilities0000
Total Liabilities£307,448.00£188,337.00£157,909.00£150,681.00
Net assets£190,588.00£657,655.00£969,080.00£1.14 m
Equity2024202320222021
Called up share capital£2.22 m£2.22 m£2.21 m£2.21 m
Share Premium£18.70 m£18.70 m£18.68 m£18.68 m
Profit / Loss-£601,998.00-£419,916.00-£299,132.00-£361,803.00
Other Equity£724,337.00£1.19 m£1.50 m£1.66 m
Preference & Minorities-£533,749.00-£531,874.00-£529,999.00-£514,022.00
Total Capital Employed£190,588.00£657,655.00£969,080.00£1.14 m
Ratios2024202320222021
Debt Ratio0000
Debt-to-Equity0000
Assets / Equity2.61322.61322.61322.6132
Cash / Equity0.99350.99350.99350.9935
EPS£-0.00£-0.00£-0.00£-0.00
Cash Flow2024202320222021
Cash from operating activities-£191,498.00-£520,739.00-£213,615.00-£262,276.00
Cashflow before financing-£191,498.00-£485,639.00-£213,615.00£786,124.00
Increase in Cash-£189,764.00-£484,752.00-£213,537.00£786,075.00
Income2024202320222021
Turnover£801,964.00£389,916.00£426,168.00£505,330.00
Cost of sales£518,169.00£95,497.00£46,119.00£49,136.00
Gross Profit£283,795.00£294,419.00£380,049.00£456,194.00
Operating Profit-£603,592.00-£420,927.00-£299,205.00-£361,916.00
Pre-Tax profit-£601,998.00-£419,916.00-£299,132.00-£361,803.00

Provexis PLC Company Background

SectorHealthcare
ActivitiesProvexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant bloodclotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.
Latest Interim Date27 Dec 2024
Latest Fiscal Year End Date30 Sep 2024

Provexis PLC Directors

AppointedNamePosition
2008-09-01Mr. Krijn RietveldNon-Executive Director
2011-12-01Mr. Steven Neil MorrisonExecutive Director,Chief Operating Officer
2011-08-09Dr. Neville Clifford BainNon-Executive Director,Deputy Chairman
2014-08-29Mr. Stephen Nigel Moon Executive Director,Chief Executive Officer
2024-09-30Mr. Charles Dawson BuckNon-Executive Director,Chairman
2024-09-30Mr. Ian FordExecutive Director,CFO, CEO and Secretary
2011-08-09Mr. Stewart William Slade BSc,ACAExecutive Director,Finance Director and Company Secretary
2024-09-30Dr. Niamh Ann O'Kennedy Executive Director,Chief Scientific Officer

Provexis PLC Contact Details

Company NameProvexis PLC
AddressProspect House, 58 Queens Road, Reading, RG1 4RP
Telephone+44 7917670260
Websitehttps://www.provexis.com

Provexis PLC Advisors

SolicitorTLT LLP
RegistrarEquiniti Ltd.
Phone+44 1214157082
StockbrokerCenkos Securities
Phone+44 2073978900
Fax+44 2073978901
Financial PR AdviserHaggie Partners LLP
Phone+44 2075624444
Nominated AdviserCenkos Securities
Phone+44 2073978900
Fax+44 2073978901